UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.
1. A method of treating diseases or disorders of the energy homeostasis, selected from the group consisting of obesity, overweight, hyperglycemia, adiposity and metabolic syndrome, in a patient comprising administering to the patient an effective amount of a composition comprising a polynucleotide selected from the group consisting of:
(i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1;
(ii) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2;
(iii) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 3;
(iv) a polynucleotide which is at least 90% identical to any one of (i) to (iii); and
(v) a polynucleotide according to (iv), which comprises the nucleotide sequence of SEQ ID NO: 6.
2. The method of claim 1 , wherein said polynucleotide is about 15 to about 100 nucleotides in length.
3. The method of claim 1 , wherein the composition contains about 1 ng/kg body weight to about 100 mg/kg body weight of said polynucleotide.
4. The method of claim 1 , wherein said polynucleotide or a nucleotide sequence encoding said polynucleotide is positioned in a vector.
5. The method according to claim 4 , wherein said vector is transduced, transformed or transfected into a cell of the patient.
6. The method of claim 1 , wherein the composition is administered parenterally, via injection, orally, rectally, via inhalation, topically or vaginally.
7. The method according to claim 1 , wherein said composition comprises two or more of said agents.
8. The method according to claim 1 , wherein said subject is a human subject.
9. The method according to claim 1 , wherein said composition comprises a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1.
10. The method according to claim 1 , wherein said composition comprises a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2.
11. The method according to claim 1 , wherein said composition comprises a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 3.
12. The method according to claim 1 , wherein said composition comprises a polynucleotide comprising the nucleotide sequence which is at least 90% identical to any one of (i) to (iii).
13. The method according to claim 1 , wherein said composition comprises a polynucleotide which is at least 90% identical to any one of (i) to (iii), and which polynucleotide comprises the nucleotide sequence of SEQ ID NO: 6.